FDA approves first new drug for lupus in 56 years — but how do the economics work?

The companies estimate there are at least 200,000 lupus patients in the U.S. who could benefit from the drug.

Analysts estimate the drug could reach annual sales exceeding $3 billion within five years.

How does this math make sense? $3 billion / 200,000 = $15,000. So (not counting sales outside the U.S.) they’re talking about each person paying fifteen grand per year for this drug alone. How do the economics of that make sense?

We have to figure out a way to bring drugs to market more efficiently. A phased rollout would let drugs come to market sooner and mitigate risk.

Advertisements

One thought on “FDA approves first new drug for lupus in 56 years — but how do the economics work?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s